Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/PLAUR_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PLAUR_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PLAUR_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/PLAUR_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PLAUR_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/PLAUR_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PLAUR_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PLAUR_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PLAUR_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PLAUR_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PLAUR_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005087818 | Prostate | Tumor | regulation of body fluid levels | 91/3246 | 379/18723 | 5.37e-04 | 3.91e-03 | 91 |
GO:002240916 | Prostate | Tumor | positive regulation of cell-cell adhesion | 70/3246 | 284/18723 | 1.06e-03 | 6.87e-03 | 70 |
GO:000717314 | Prostate | Tumor | epidermal growth factor receptor signaling pathway | 32/3246 | 108/18723 | 1.12e-03 | 7.14e-03 | 32 |
GO:003411011 | Prostate | Tumor | regulation of homotypic cell-cell adhesion | 13/3246 | 33/18723 | 2.26e-03 | 1.28e-02 | 13 |
GO:00341121 | Prostate | Tumor | positive regulation of homotypic cell-cell adhesion | 7/3246 | 13/18723 | 3.02e-03 | 1.61e-02 | 7 |
GO:000759614 | Prostate | Tumor | blood coagulation | 53/3246 | 217/18723 | 4.89e-03 | 2.39e-02 | 53 |
GO:005081714 | Prostate | Tumor | coagulation | 54/3246 | 222/18723 | 4.95e-03 | 2.42e-02 | 54 |
GO:000759914 | Prostate | Tumor | hemostasis | 53/3246 | 222/18723 | 7.87e-03 | 3.50e-02 | 53 |
GO:009719329 | Skin | cSCC | intrinsic apoptotic signaling pathway | 150/4864 | 288/18723 | 1.76e-21 | 3.34e-19 | 150 |
GO:200123329 | Skin | cSCC | regulation of apoptotic signaling pathway | 173/4864 | 356/18723 | 2.25e-20 | 3.44e-18 | 173 |
GO:200124229 | Skin | cSCC | regulation of intrinsic apoptotic signaling pathway | 96/4864 | 164/18723 | 9.88e-19 | 1.32e-16 | 96 |
GO:005109827 | Skin | cSCC | regulation of binding | 152/4864 | 363/18723 | 2.21e-11 | 1.10e-09 | 152 |
GO:200123429 | Skin | cSCC | negative regulation of apoptotic signaling pathway | 101/4864 | 224/18723 | 4.17e-10 | 1.70e-08 | 101 |
GO:005254728 | Skin | cSCC | regulation of peptidase activity | 177/4864 | 461/18723 | 2.21e-09 | 8.02e-08 | 177 |
GO:200124327 | Skin | cSCC | negative regulation of intrinsic apoptotic signaling pathway | 53/4864 | 98/18723 | 2.91e-09 | 1.02e-07 | 53 |
GO:005254828 | Skin | cSCC | regulation of endopeptidase activity | 165/4864 | 432/18723 | 1.18e-08 | 3.63e-07 | 165 |
GO:000863726 | Skin | cSCC | apoptotic mitochondrial changes | 55/4864 | 107/18723 | 1.63e-08 | 4.91e-07 | 55 |
GO:0010821111 | Skin | cSCC | regulation of mitochondrion organization | 67/4864 | 144/18723 | 7.99e-08 | 1.96e-06 | 67 |
GO:004328128 | Skin | cSCC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 89/4864 | 209/18723 | 1.20e-07 | 2.79e-06 | 89 |
GO:200011628 | Skin | cSCC | regulation of cysteine-type endopeptidase activity | 97/4864 | 235/18723 | 2.01e-07 | 4.34e-06 | 97 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLAUR | SNV | Missense_Mutation | rs750492027 | c.829N>A | p.Ala277Thr | p.A277T | Q03405 | protein_coding | tolerated(0.19) | benign(0.018) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLAUR | SNV | Missense_Mutation | | c.198N>G | p.Ser66Arg | p.S66R | Q03405 | protein_coding | deleterious(0) | benign(0.284) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PLAUR | insertion | In_Frame_Ins | novel | c.389_390insTCCCCTGGCCCCCATAGGGCGTCCAAAGGATGA | p.Gly130_Arg131insProLeuAlaProIleGlyArgProLysAspAsp | p.G130_R131insPLAPIGRPKDD | Q03405 | protein_coding | | | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PLAUR | SNV | Missense_Mutation | | c.346G>A | p.Glu116Lys | p.E116K | Q03405 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PLAUR | SNV | Missense_Mutation | rs756038834 | c.814N>A | p.Ala272Thr | p.A272T | Q03405 | protein_coding | tolerated(0.3) | benign(0.042) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLAUR | SNV | Missense_Mutation | | c.118G>T | p.Ala40Ser | p.A40S | Q03405 | protein_coding | tolerated(0.21) | benign(0.028) | TCGA-AF-4110-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | oxaliplatin | SD |
PLAUR | SNV | Missense_Mutation | novel | c.979N>A | p.Leu327Met | p.L327M | Q03405 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.533) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLAUR | SNV | Missense_Mutation | novel | c.389N>A | p.Gly130Asp | p.G130D | Q03405 | protein_coding | deleterious(0.01) | benign(0.264) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLAUR | SNV | Missense_Mutation | novel | c.668N>T | p.Ser223Ile | p.S223I | Q03405 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLAUR | SNV | Missense_Mutation | | c.252N>T | p.Lys84Asn | p.K84N | Q03405 | protein_coding | deleterious(0.03) | benign(0.213) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | ADENOVIRAL VECTOR | | 12955075 |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | UROKINASE | UROKINASE | |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | RECOMBINANT INTERFERON GAMMA | | 8049441 |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | G-CSF | FILGRASTIM | 15747404 |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | MCP-2 | | 12138365 |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | DIPHTHERIA TOXIN | | 11959893 |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | Ruxolitinib | RUXOLITINIB | |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | PHORBOL MYRISTATE ACETATE | | 9531044 |